載入中
NASDAQHealthcareBiotechnology
最新資料
US$11.29
+US$0.08 · +0.71%
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
前收盤價
US$11.29
+US$0.08 · +0.71%
盤後
US$11.29
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
日內區間
目前US$11.29
52週區間
目前US$11.29
盤中時間採用ET。市場資料可能有所延遲。
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
日內區間
目前US$11.29
52週區間
目前US$11.29
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（AUD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 12.05億 AUD | 7.83億 AUD | 5.03億 AUD | 1.6億 AUD | 759.6萬 AUD |
| 銷貨成本 | 5.65億 AUD | 2.74億 AUD | 1.88億 AUD | 6517萬 AUD | 3868.22萬 AUD |
| 毛利 | 6.4億 AUD | 5.1億 AUD | 3.14億 AUD | 9492.6萬 AUD | 504.8萬 AUD |
| 研究與開發 | 2.57億 AUD | 1.21億 AUD | 1.29億 AUD | 5785.7萬 AUD | 3413.5萬 AUD |
| 銷售、一般及管理費用 | 3.57億 AUD | 2.07億 AUD | 1.34億 AUD | 8709.8萬 AUD | 4698.6萬 AUD |
| 營業費用 | 6.14億 AUD | 4.28億 AUD | 2.63億 AUD | 1.87億 AUD | 5330.26萬 AUD |
| 利息收入 | 873.71萬 AUD | 1086.2萬 AUD | 67.1萬 AUD | 1000 AUD | — |
| 利息支出 | 5506.34萬 AUD | 2146.4萬 AUD | 894.3萬 AUD | 40.6萬 AUD | 19.57萬 AUD |
| 折舊和攤銷 | 3266.58萬 AUD | 802.68萬 AUD | 674.3萬 AUD | 537.9萬 AUD | 517.4萬 AUD |
| 營業利益 | 2664.17萬 AUD | 8213萬 AUD | 1584萬 AUD | −9193萬 AUD | −8124.7萬 AUD |
| 淨利 | −1068.52萬 AUD | 4991.9萬 AUD | 521.1萬 AUD | −1.04億 AUD | −8051萬 AUD |
公司資料更新於 2026年10月13日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$18.00
上漲空間 59.43%報告持有此股票曝險的交易所交易基金。
Schwab International Equity ETFSCHF1847.44萬0.03%674.08億 USD0.03%US$27.13-0.51%
State Street SPDR Portfolio Developed World ex-US ETFSPDW1035.1萬0.03%404.62億 USD0.03%US$49.69-0.58%
Schwab Fundamental International Small Company Index ETFFNDC517.53萬0.17%30.73億 USD0.39%US$49.50-0.48%
John Hancock Investments - Multifactor Developed International ETFJHMD94.74萬0.10%9.65億 USD0.39%US$43.96-0.29%
State Street SPDR Portfolio Europe ETFSPEU35.14萬0.05%6.89億 USD0.07%US$53.02-0.21%
State Street SPDR MSCI EAFE StrategicFactors ETFQEFA24.9萬0.03%9.96億 USD0.30%US$97.45-0.24%
State Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAX21.31萬0.04%4.88億 USD0.20%US$53.12-0.38%
ActivePassive International Equity ETFAPIE13.14萬0.01%11.41億 USD0.45%US$38.40-0.41%Schwab International Equity ETFSCHFState Street SPDR Portfolio Developed World ex-US ETFSPDWSchwab Fundamental International Small Company Index ETFFNDCJohn Hancock Investments - Multifactor Developed International ETFJHMDState Street SPDR Portfolio Europe ETFSPEUState Street SPDR MSCI EAFE StrategicFactors ETFQEFAState Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAXActivePassive International Equity ETFAPIEAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
